The role of mpMRI for low and intermediate risk prostate cancer during active surveillance
The widespread use of prostate-specific antigen (PSA) as a screening test has led to a decrease in cancer-related mortality but also to an increased detection of patients with low risk prostate cancer at biopsy. Risk stratification for prostate cancer is based on different parameters such as clinical stage, PSA, Gleason score at biopsy and an […]
Dr Francesco Giganti, Professor Caroline Moore
University College London, University College Hospitals NHS Foundation Trust